A Study of GLB-001
Phase 1
48
about 2.7 years
18+
8 sites in CA, KS, NY +1
About this study
This trial is testing a new treatment called GLB-001 in people with leukemia or myelodysplastic syndromes that have returned after treatment. The goal is to see if this medication is safe and how it works in the body.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take GLB-001
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Dose-limiting Toxicity (DLT), Incidence of Adverse Events (AEs), Maximum Tolerated Dose (MTD)/Maximum Administered Dose (MAD), Recommended Phase 2 Dose (RP2D)
Secondary: CR Rate in Participants with Higher Risk Myelodysplastic Syndromes (HR-MDS), CR with Incomplete Hematologic Recovery (CRi) Rate in Participants with AML, CR with Partial Hematological Recovery (CRh) Rate in Participants with AML, Complete Remission (CR) Rate in Participants with AML, DOR in Participants with HR-MDS, Duration of Remission or Response (DOR) in Participants with AML, GLB-001 Pharmacokinetics-AUC0-24, GLB-001 Pharmacokinetics-AUC0-last
Oncology